Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04928339
Other study ID # 2021-0111
Secondary ID Protocol Version
Status Completed
Phase Phase 4
First received
Last updated
Start date March 28, 2022
Est. completion date November 30, 2023

Study information

Verified date January 2024
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to see if bilateral pecto-intercostal fascial plane blocks (PIFB) with a mixture of liposomal and standard bupivacaine decrease pain and opioid requirements in patients undergoing cardiac surgery via median sternotomy compared to controls (sham blocks with saline). 100 participants will be recruited and can expect to be on study for 100 days.


Description:

Thousands of heart surgeries are performed every day in the United States. Unattenuated perioperative pain has been shown to contribute to increased morbidity, mortality, length of stay, and healthcare costs. Practice guidelines from the American Society of Regional Anesthesiologists recommend pre-incision techniques to reduce perioperative pain, however in cardiac surgery, there are no commonly used techniques to follow this recommendation. The PIFB is a newly described fascial plane block and existing literature supports the safety and efficacy of the PIFB in cardiac surgery patients. However, there are no randomized controlled trials evaluating this technique with a long-acting depot local anesthetic. The purpose of this study is to determine whether bilateral pecto-intercostal fascial plane blocks with liposomal bupivacaine decrease pain and opioid requirements in patients undergoing cardiac surgery via median sternotomy compared to controls (sham blocks with saline). The primary hypothesis is that patients receiving effective regional anesthesia with liposomal bupivacaine via PIFB will demonstrate a clinically significant (25%) reduction in total daily opioid consumption through 72 hours postoperatively compared to patients receiving standard of care without effective regional anesthesia (saline only via PIFB). This study is a prospective, single-center, randomized, double-blind, controlled trial to evaluate whether bilateral pecto-intercostal fascial plane blocks with liposomal and standard bupivacaine decrease pain and opioid requirements in patients undergoing cardiac surgery via median sternotomy compared to controls (sham blocks with saline). The participants will be randomized to receive bilateral PIFB with a mixture of standard and liposomal bupivacaine or bilateral PIFB with saline only. Recovery characteristics, including opioid consumption, pain scores, duration of mechanical ventilation, ICU length of stay, hospital length of stay, side effects, and chronic opioid use will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date November 30, 2023
Est. primary completion date September 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Participant provides consent to participate in study - Ideal body weight (IBW) is >50kg - Participant is planned to undergo coronary artery bypass graft or single valve repair/replacement surgery via median sternotomy - Participant is undergoing an elective procedure Exclusion Criteria: - Participant is unable or unwilling to give consent - Non-English speaking - Known or believed to be pregnant or is currently breastfeeding - Participant is a prisoner - Clinically unstable per discretion of the Investigator - Participant requires urgent/emergent surgery - History of previous sternotomy - Preoperative coagulopathy (INR >1.4, platelets <100,000) or ongoing anticoagulation or anti-platelet therapy (except aspirin 81mg) - Allergy or sensitivity to amide-type local anesthetics, dexmedetomidine or ketamine - Participant has decompensated heart failure - Severe left ventricle dysfunction (defined quantitatively as an ejection fraction of less than or equal to 35%) or right ventricle dysfunction (defined qualitatively as "severe") - Diagnosis of cirrhosis or end-stage liver disease - Requires the use of mechanical circulatory support pre-operatively - Participant uses chronic opioids (meaning at the time of the preoperative screening evaluation by the study team, the patient is prescribed and taking any opioid pain medication)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupivacaine Injection
10mL of 0.25% bupivacaine
Liposomal bupivacaine
15mL of 133mg liposomal bupivacaine
Other:
Saline
25mL saline control

Locations

Country Name City State
United States University of Wisconsin Hospital and Clinics Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Opioid Consumption 72 hours postoperatively Total opioid consumption during the initial 72 hours postoperatively will be measured in morphine equivalents and compared between groups. up to 72 hours post-op
Secondary Total Intraoperative Opioid Consumption Total intraoperative opioid consumption will be measured in morphine equivalents and compared between groups. intraoperative
Secondary Daily Mean Pain Scores first 72 hours Postoperatively Pain will be assessed, according to standard of care, every 4 hours using the 11-point Numerical Rating Scale (NRS), beginning at time 0 (arrival to ICU). Each patient's pain scores (higher scores indicate worse pain) within each postoperative day will be averaged, and the mean pain scores during each day and throughout the first 72 hours will be compared between the intervention and control groups. up to 72 hours post-op
Secondary Maximum Pain Scores up to 72 hours Postoperatively Pain will be assessed, according to standard of care, every 4 hours using the 11-point Numerical Rating Scale (NRS) where higher score indicate worse pain, beginning at time 0 (arrival to ICU). Maximum pain scores will be compared between groups. up to 72 hours post-op
Secondary Pain Score at 90 days Postoperatively Pain will be assessed, according to standard of care, every 4 hours using the 11-point Numerical Rating Scale (NRS) where higher score indicate worse pain. Pain at 90 days postoperative will be surveyed by phone. up to 90 days post-op
Secondary Daily Opioid Consumption up to 72 hours Postoperatively Daily opioid consumption during the initial 72 hours postoperatively will be measured in morphine equivalents and compared between groups. up to 72 hours post-op
Secondary Hours of Mechanical Ventilation after ICU admission Duration of mechanical ventilation will be measured by hours of mechanical ventilation after admission to the ICU. up to 72 hours post-op
Secondary Number of postoperative days until the first Bowel Movement Return of bowel function will be measured in the number of postoperative days until the first bowel movement. up to 72 hours post-op
Secondary Incidence of Postoperative Delirium per the Confusion Assessment Method for the ICU (CAM-ICU) Postoperative delirium will be measured according to standard of care by utilizing the CAM-ICU assessment every 8-12 hours. The CAM-ICU determines either 'yes' or 'no' the participant is experiencing delirium. up to 72 hours post-op
Secondary Number of Hours that the Patient is in the ICU Duration of ICU stay will be measured by the number of hours that the patient is in the ICU until an order is placed for transfer to a lower level of care. up to 72 hours post-op
Secondary Number of post-operative days until the Patient is Discharged Duration of hospital stay will be measured by the number of post-operative days until the patient is discharged. up to 7 days
Secondary Number of Participants Using Opioids at 90 days Postoperatively Patient use of opioids at 90 days will be obtained by phone call. up to 90 days post-op
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2